Ongoing initiatives in key CSR areas
First written in FY2016. 3 of 9 entries say "Restated". Latest entry: 2026-09-30.
Ono Pharmaceutical moved to the "Worse" side of this theme in 2022.
1 other company's latest entry also says "Restated".
- FY2025AdvancedAnnual report
「Each materiality has been clearly linked to the growth strategy in the medium-term management plan, and KPIs have been established to develop a management structure with greater momentum. The status and progress of initiatives for each materiality are also reflected in the performance evaluations of directors.」
Sustainability materialities have been linked to the growth strategy through KPIs, and the process has been made more specific by reflecting progress in directors’ performance evaluations. - FY2024AdvancedAnnual report
「Progress on initiatives addressing environmental issues, including climate change, discussed by the Sustainability Strategy Committee and the Environmental Committee is reported to the Board of Directors at least once every quarter, and the directors oversee the execution of decisions made.」
For sustainability and environmental issues, reporting to the Board of Directors is required at least once per quarter, making the oversight structure more specific. - FY2023ReframedAnnual report
「Important matters relating to our sustainability strategy, including climate change measures, are discussed by the Sustainability Strategy Committee, which was newly established in fiscal 2022. Matters discussed and decided by the Sustainability Strategy Committee are reported to the Board of Directors at least once every 6 months, and the directors oversee the execution of those decisions.」
In addition to the existing sustainable management policy, a governance structure involving the Sustainability Strategy Committee and reporting to the Board of Directors has been explicitly described. - FY2022ReframedAnnual report
「To contribute to the realization of a sustainable society through our business activities, we have established a sustainable management policy that integrates financial and nonfinancial management issues and links them to value creation, and are advancing initiatives addressing key issues.」
The previous explanation of the key CSR areas has been reorganized as a sustainable management policy that integrates financial and nonfinancial issues and links them to value creation. - FY2018RestatedAnnual report
「In our corporate social responsibility (CSR) activities, we have identified corporate governance, innovative pharmaceuticals, talent and human rights, the environment, fair business practices and society as key areas requiring action, and will advance initiatives to fulfill our social responsibilities to all stakeholders.」
The 6 key CSR areas and the policy of fulfilling our social responsibilities to all stakeholders have been reaffirmed. - FY2017RestatedAnnual report
「In our corporate social responsibility (CSR) activities, we have identified corporate governance, innovative pharmaceuticals, talent and human rights, the environment, fair business practices and society as key areas requiring action, and will advance initiatives to fulfill our social responsibilities to all stakeholders.」
The 6 key CSR areas and the policy of fulfilling our social responsibilities to all stakeholders have been reaffirmed. - FY2016First statedAnnual report
「We have identified corporate governance, innovative pharmaceuticals, talent and human rights, the environment, fair business practices and society as key areas requiring action, and are advancing initiatives to fulfill our social responsibilities to all stakeholders.」
The key CSR areas have been organized into 6 categories, demonstrating an ongoing commitment to fulfilling our social responsibilities to all stakeholders.